Giant-Cell Arteritis Market Is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – AbbVie, Regeneron, Novartis, IDEC Pharmaceuticals, and Others

Delveinsight Business Research LLP
DelveInsight’s “Giant-Cell Arteritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Giant-Cell Arteritis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Giant-Cell Arteritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Giant-Cell Arteritis: An Overview

According to the National Centre for Advancing Translational Sciences” Giant-Cell Arteritis (GCA, also known as Temporal arteritis; Cranial Arteritis; Granulomatous Arteritis and Horton’s disease) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow”.

Giant-Cell Arteritis Market Key Facts

According to the data of the Arthritis Foundation, Caucasian women over the age of 50 (most commonly between the ages of 70 and 80 years), have the highest risk of developing Giant-Cell Arteritis. Although women are more likely than men to develop GCA, research suggests that men are more likely to suffer potentially blinding eye involvement.

The disease occurs most frequently in populations of Northern Europe, and in particular in Scandinavian countries where the incidence has been reported as high as 32.8 per 100,000 inhabitants over the age of 50 years.

According to the National Organization for Rare Diseases (NORD,), Giant-Cell Arteritis occurs in approximately 24 in 100,000 people over the age of 50 years, affecting twice as many females as males. Also, GCA affects 110,000 individuals in the United States.

Giant-Cell Arteritis Market

The Giant Cell Arteritis market is expected to grow during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Giant-Cell Arteritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Giant-Cell Arteritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Giant-Cell Arteritis Epidemiology

The epidemiology section covers insights about the historical and current Giant-Cell Arteritis patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Giant-Cell Arteritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant-Cell Arteritis market or expected to get launched in the market during the study period. The analysis covers Giant-Cell Arteritis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Giant-Cell Arteritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/giant-cell-arteritis-market

Giant-Cell Arteritis Therapeutics Analysis

The Giant-Cell Arteritis market dynamics is anticipated to change in the coming years, owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. 

Some of the key companies in the Giant Cell Arteritis market include:

AbbVie

Regeneron Pharmaceuticals

Novartis Pharmaceuticals

IDEC Pharmaceuticals

And others.

Giant Cell Arteritis Therapies Covered in the report include:

Upadacitinib

Secukinumab

KEVZARA (sarilumab)

And many others.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-  https://www.delveinsight.com/sample-request/giant-cell-arteritis-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Giant-Cell Arteritis Competitive Intelligence Analysis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Giant-Cell Arteritis Disease Background and Overview

6. Giant-Cell Arteritis Patient Journey

7. Giant-Cell Arteritis Epidemiology and Patient Population

8. Giant-Cell Arteritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Giant-Cell Arteritis Unmet Needs

10. Key Endpoints of Giant-Cell Arteritis Treatment

11. Giant-Cell Arteritis Marketed Products

12. Giant-Cell Arteritis Emerging Therapies

13. Giant-Cell Arteritis Seven Major Market Analysis

14. Attribute Analysis

15. Giant-Cell Arteritis Market Outlook (7 major markets)

16. Giant-Cell Arteritis Access and Reimbursement Overview

17. KOL Views on the Giant-Cell Arteritis Market.

18. Giant-Cell Arteritis Market Drivers

19. Giant-Cell Arteritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/giant-cell-arteritis-market

Other Latest Reports By DelveInsight

Bevacizumab Biosimilars Insight

DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/